NASDAQ · ENGNW
Healthcare · Biotechnology
$0.18
Down-$0.05 (-21.14%)
Updated Nov 3, 2026, 1:52 PM
SID Score
2.8/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · ENGNW
1M range · 10 trading sessions · Daily adjusted prices
Prices through Oct 28, 2026
ENGNW closed at $0.18 after 10 trading sessions, up 6.65% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 28, 2026 | $0.1815 | $0.1831 | $0.1813 | $0.1813 | 2.31K |
| Oct 23, 2026 | $0.2087 | $0.2399 | $0.20 | $0.2299 | 2.66K |
| Oct 22, 2026 | $0.1501 | $0.1899 | $0.15 | $0.1899 | 4.06K |
| Oct 21, 2026 | $0.167 | $0.167 | $0.165 | $0.165 | 1.99K |
| Oct 20, 2026 | $0.1725 | $0.1764 | $0.1491 | $0.175 | 52.05K |
| Oct 19, 2026 | $0.15 | $0.1699 | $0.15 | $0.1699 | 12.99K |
| Oct 16, 2026 | $0.1338 | $0.1899 | $0.1301 | $0.17 | 14.58K |
| Oct 15, 2026 | $0.1302 | $0.168 | $0.1301 | $0.168 | 19.41K |
| Oct 14, 2026 | $0.131 | $0.1599 | $0.1308 | $0.1599 | 801 |
| Oct 5, 2026 | $0.25 | $0.25 | $0.1416 | $0.17 | 63.67K |
The latest Smart Investors Daily articles mentioning ENGNW.
Company
Market Activity
Research & News
ENGNW research
Company profile and research snapshot.
enGene Holdings Inc is a clinical-stage biotechnology company focused on developing gene therapies to improve the lives of patients. The Company is developing non-viral gene therapies based on its novel and proprietary dually derived chitosan, or DDX, gene delivery platform, which allows localized delivery of multiple gene cargos directly to mucosal tissues and other organs.
Visit company websiteConsensus and target data currently published for this company.
No generated briefing is available yet.
SeekingAlpha · Oct 19, 2026
2026-10-19. The following slide deck was published by enGene Therapeutics Inc.
Yahoo · Oct 16, 2026
enGene (NASDAQ:ENGN) used a company webinar to outline preclinical findings for its investigational non-viral gene therapy, detalimogene voraplasmid, used with a polidocanol surfactant bladder rinse, while community urologists discussed the treatment burden facing patients with high-risk non-muscle
SeekingAlpha · Oct 15, 2026
enGene Therapeutics Inc. (ENGN) Discusses Preclinical Data and Clinical Case Studies on Incorporating Surfactant Bladder Rinse into Treatment October 15,...
Yahoo · Oct 13, 2026
BOSTON & MONTREAL, October 13, 2026--enGene Therapeutics Inc. (Nasdaq: ENGN, "enGene" or the "Company"), a clinical-stage, non-viral genetic medicines company, today announced that it will host a webinar on Thursday, October 15, 2026 at 10:00 AM ET that will provide greater detail on the preclinical data supporting the incorporation of its surfactant bladder rinse plus detalimogene voraplasmid (detalimogene) into clinical development for Bacillus Calmette-Guérin (BCG)-unresponsive, high-risk, no
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning ENGNW.
